Farzad Kompani

Farzad Kompani

Auto-generated profile, based on publicly available information

Farzad Kompani

Division of Hematology and Oncology, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMelika Hanifiha
Melika Hanifiha
AGAli Ghanbari
Ali Ghanbari
MKMohammad Keykhaei
Mohammad Keykhaei
SMSahar Saeedi Moghaddam
Sahar Saeedi Moghaddam
NRNegar Rezaei
Negar Rezaei
FFFarshad Farzadfar
Farshad Farzadfar
Purpose: To express a global view of care quality in major causes of mortality and morbidity in children and adolescences Methods: We used primary epidemiologic indicators from the Global Burden of Disease 1990–2017 database. We have created four secondary indices from six primary indices in order to assess the care quality parameters. We conducted a principal component analysis on incidence, prevalence, mortality, Years of Life Lost (YLLs), Years Lived with Disability (YLDs), and Disability Adjusted Life Years (DALYs) to create an index presented by quality-of-care index (QCI) to compare different countries. Results: The global QCI scores of respiratory infection, enteric infection, leukemia, foreign body aspiration, asthma, epilepsy, diabetes mellitus, dermatitis, road injury, and neonatal disorders have improved remarkably. These causes showed equal distribution of qualified care for both sexes. The global trend of QCI score for mental health showed a steady pattern during the same time and disparities favoring females was evident. The quality of care for these causes was notably higher in developed areas. Conclusions: The global QCI revealed a universal growth in major causes of death and morbidity in <20y during 28 years. Quality of care is an associate of the level of country’s development. Despite effective interventions, inequities still remain. Implementation of policies to invest in quality improvement and inequality elimination is needed.

14 January 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MSMahsima Shabani
Mahsima Shabani
SMSahar Saeedi Moghaddam
Sahar Saeedi Moghaddam
BABahar Ataeinia
Bahar Ataeinia
NRNazila Rezaei
Nazila Rezaei
FMFarnam Mohebi
Farnam Mohebi
FFFarshad Farzadfar
Farshad Farzadfar
Background: Childhood cancer is a double-edged sword, considering its high rate of response to treatment despite a high vulnerability to develop future malignancies in survivors. Thus, multidisciplinary preventive, curative, and supportive strategies must be incorporated in childhood cancer care that require understanding the distribution and trend of cancer in the target population. In this article, we aimed to report the national and subnational trends of childhood cancer incidence in Iran from 1990 to 2016, and mortality/incidence ratio (MIR), which, to our knowledge, have not been reported in previous literature. Method: Data on the incidence and mortality rates were collected from the National and Subnational Burden of Diseases project. We employed a two-stage spatiotemporal model to estimate cancer incidences by sex, age, province, and year based on the primary dataset of national death registration system. National and subnational age and gender-specific trends as well as MIR were calculated. Result: The age-standardized incidence rate had a steady increasing trend for cancers in both female [annual percent change (APC), 1.6%] and male (APC, 2.1%) patients. Not only there was an increasing trend in most provinces but also there was a 40% divergence in age-standardized incidence rate at subnational levels. Leukemia, lymphoma, neoplasms of the central nervous system (CNS), digestive tract, endocrine gland, and urinary tract were the leading causes of cancer comprising more than half of all cancers. There was a remarkable general decrease in MIR by 75% as a proxy of care quality. Conclusion: Regarding the increased trend of childhood cancer incidence, there is an essential need to address the etiologic factors and establish preventive plans for childhood cancers. Despite the favorable outcomes observed in cancer care, commensurate health resource allocation must be applied to diminish the subnational disparities.

1 October 2019 in Croatian Medical Journal
Verified
Journal Article
Open access
SSSoheila Sobhani
Soheila Sobhani
FRFarzaneh Rahmani
Farzaneh Rahmani
MRMaryam Rahmani
Maryam Rahmani
MAMarzieh Askari
Marzieh Askari
FKFarzad Kompani
Farzad Kompani
To determine whether serum ferritin, liver transaminases, and regularity and type of iron chelation protocol can be used to predict liver iron load as assessed by T2* magnetic resonance imaging (MRI) in patients with beta thalassemia major (TM).This cross-sectional ...

30 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAmirhossein Poopak
Amirhossein Poopak
SMSahar Saeedi Moghaddam
Sahar Saeedi Moghaddam
ZEZahra Esfahani
Zahra Esfahani
MKMohammad Keykhaei
Mohammad Keykhaei
NRNegar Rezaei
Negar Rezaei
FKFarzad Kompani
Farzad Kompani
Background: Hematologic malignancies have a great essential role in cancer global burden. Leukemia which two major subtypes based on the onset, is one of the common subtypes of this malignancy. Method: For the GBD 2019 study, cancer registry data and vital registration system were used to estimate leukemia mortality. The Meta-Regression-Bayesian Regularized Trimmed (MR-BRT), Cause of Death Ensemble model (CODEm) and Spatiotemporal Gaussian Process Regression (ST-GPR) were used to model our data and estimate each quantity of interest. Mortality to incidence ratios (MIR) were used to generate incidence and survival from mortality rate. Prevalence and survival were used to generate years lived with disability (YLDs). Age-specific mortality and life expectancy at the same age were used to estimate years of life lost (YLLs). The sum of YLLs and YLDs generates DALYs. Results: The total national incidence of leukemia increased from 6092 (UI 95%: 3803–8507) in 1990 to 6767 (4646–7890) new cases in 2019. However, leukemia age-standardized incidence ratio(ASIR) decreased from 11.6 (8–14.8) to 8.9 (6.2–10.3) new cases per 100,000 in this exact period. At the national level, deaths from leukemia increased 1.5-fold between 1990 and 2019, from 3287 (2284–4201) to 4424 (3137–5030), whereas the age-standardized death rate(ASDR) decreased from 8.3 (6.1–9.8) in 1990 to 6 (4.3–6.8) per 100,000 in 2019. In the study period, total leukemia DALYs decreased 12.2% and reached 162850 (110681–188806), in 2019. The age-standardized DALYs decreased 36.7% from 324.3 (224.8–413.4) in 1990 to 205.3 (140.3–237.8) in 2019. ASDR, DALYs, YLLs, and YLDs rate to high BMI was increasing while smoking and occupational exposure to benzene and formaldehyde were decreasing in the study period. Conclusion: This study provided a better understanding of leukemia burden and to reduce controversies of leukemia across Iran. The leukemia status alteration of the country, is trackable.

9 January 2023 in Cancer Medicine
Verified
Journal Article
Open access
MMMahdi Mahdavi
Mahdi Mahdavi
SMSahar Saeedi Moghaddam
Sahar Saeedi Moghaddam
MAMohsen Abbasi‐Kangevari
Mohsen Abbasi‐Kangevari
EMEsmaeil Mohammadi
Esmaeil Mohammadi
PSParnian Shobeiri
Parnian Shobeiri
FKFarzad Kompani
Farzad Kompani
Introduction: Central nervous system cancers (CNS cancers) impose a significant burden upon healthcare systems worldwide. Currently, the lack of a comprehensive study to assess various epidemiological indexes of CNS cancers on national and subnational scales in Iran can hamper healthcare planning and resource allocation in this regard. This study aims to fill this gap by providing estimates of CNS cancer epidemiological measures on national and subnational levels in Iran from 1990 to 2019.Materials and Methods: This study is a part of Global Burden of Disease (GBD) 2019 that contains epidemiological measures including prevalence, incidence, mortality, Disability‐Adjusted Life Years (DALYs), Years Lived with Disability (YLDs), and Years of Life Lost (YLLs) of CNS cancers. Age standardization was utilized for comparing different provinces.Results: In 2019, 5811 (95% Uncertainty Interval: 2942–7046) national new cases and 3494 (1751–4173) deaths due to CNS cancers were reported. National age‐standardized incidence (ASIR), deaths (ASDR), and DALYs rates were 7.3 (3.7–8.8), 4.6 (2.3–5.5), and 156.4 (82.0–187.0) per 100,000 in 2019, respectively. Subnational results revealed that ASDR and ASIR have increased in the past 30 years in all provinces. Although incidence rates have increased in all age groups and genders since 1990, death rates have remained the same for most age groups and genders except for young patients aged under 15, where a decrease in mortality and YLLs can be observed.Conclusion: The incidence, deaths, and DALYs of CNS cancers increased at national and subnational levels. These findings should be considered for planning and resource allocation.

8 March 2023 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
AKAmirali Karimi
Amirali Karimi
SMSahar Saeedi Moghaddam
Sahar Saeedi Moghaddam
SASina Azadnajafabad
Sina Azadnajafabad
ZEZahra Esfahani
Zahra Esfahani
YTYeganeh Sharifnejad Tehrani
Yeganeh Sharifnejad Tehrani
FKFarzad Kompani
Farzad Kompani
Introduction: Despite the significant burden of childhood and adolescent cancers, no specific studies recently discussed the burden of cancer in this group in the North Africa and the Middle East (NAME) region. Therefore, we aimed to study the burden of cancers in this group in this region. Materials and methods: We retrieved the Global Burden of Disease (GBD) data for children and adolescent cancers (0–19 years old) in the NAME region from 1990 to 2019. 21 types of neoplasms were grouped as “neoplasms”, comprising 19 specific cancer groups as well as “other malignant neoplasms” and “other neoplasms”. Three significant parameters of incidence, deaths, and Disability-Adjusted Life Years (DALYs) were studied. The data are presented with 95% uncertainty intervals (UI), and reported rates per 100,000. Results: In 2019, almost 6 million (95% UI: 4.166 M–8.405 M) new cases and 11,560(9770-13,578) deaths due to neoplasms occurred in the NAME region. Incidence was higher in females (3.4 M), while deaths (6226 of overall 11,560) and DALYs (501,118 of overall 933,885) were estimated as higher in males. Incidence rates did not significantly change since 1990, while deaths and DALYs rates declined significantly. After excluding “other malignant neoplasms” and “other neoplasms”, leukemia was responsible for the highest number of incidence and deaths (incidence: 10,629(8237-13,081), deaths: 4053(3135-5013), followed by brain and central nervous system cancers (incidence: 5897(4192-7134), deaths: 2446(1761-2960)), and non-Hodgkin lymphoma (incidence: 2741 (2237-3392), deaths: 790(645–962)). Incidence rates of neoplasms were similar for most countries, but countries varied more in terms of death rates. Afghanistan 8.9(6.5–11.9), Sudan 6.4(4.5–8.6), and the Syrian Arab Republic 5.6(4.3–8.3) had the highest overall death rates. Conclusion: The NAME region is observing relatively constant incidence rates and a decreasing pattern in the deaths and DALYs. Despite this success, several countries are lagging behind in development. Different issues such as economic problems, armed conflicts and political instabilities, lack of equipment or experienced staff or poor distribution, stigmatization and disbelief in the healthcare systems account for unfavorable numbers in some countries. Such problems require urgent solutions as new sophisticated and personalized cares raise the alarm for even more inequalities between high and low-income countries.